eMDs acquires Aprima, boosting outpatient EHR offerings

Healthcare IT News | February 01, 2019

Electronic health record developer eMDs is acquiring Aprima Medical Software for an undisclosed sum. The addition of Aprima, which develops EHR, practice management and revenue cycle management technology, will help eMDs better serve its 63,000 provider customers worldwide, the company said. Both companies had independently worked on modernizing their product lines before this deal came together, eMDs points out, which will help when it comes to integrating the technologies and expanding them across their combined client bases. "Together, we can service a broad range of specialties and meet the evolving needs of our client partners," said eMDs CEO Derek Pickell in a statement.

Spotlight

What do I do if my child suffers a concussion?  1. Remove your child from the game 2. Have your child evaluated by a qualified healthcare professional. 3. Do not return your child to play until he or she is symptom-free 4. Inform your child’s teacher and coach about the concussion.


Other News
HEALTH TECHNOLOGY

HeartBeam Expands Patient Population for Emergency Department Software Technology Solution

HeartBeam, Inc. | July 04, 2022

HeartBeam, Inc. a developmental stage digital healthcare company with a proprietary ECG telemedicine technology for heart attack detection, announced that HeartBeam is expanding the available patient population for the Company’s Emergency Department software technology solution. In evaluating the ECG database for the clinical validation of HeartBeam’s platform technology, a significant portion of consecutive patients fell into the category of unstable angina, a serious cardiac condition. In light of the most recent 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain and in consultation with its clinical advisors, HeartBeam elected to include the full data set for clinical validation studying in support of the 510K submission. The expanded scope of the clinical validation study will provide access to a broader patient population for HeartBeam’s technology once cleared by the FDA. Due to the expanded available patient population, HeartBeam expects to file a 510K with the full data set for clinical validation no later than August 15, 2022 and does not affect the timeline for 510K submission of the Telehealth product. “It is important to include unstable angina as a diagnosis for analysis. Patients with unstable angina may have subtle electrical changes brought on by ischemia without definitive injury to the cardiac tissue. Given HeartBeam’s advanced technology solution, there is potential to identify patients who cannot be diagnosed by traditional ECG capabilities but may require intervention.” Russell Jones, MD, Interventional Cardiologist, Chair of the Ischemia Performance Improvement Committee at Phoebe Putney Health System HeartBeam’s platform technology is anticipated to assist physicians in identifying patients who present with chest pain to facilitate rapid detection of a heart attack and determine an appropriate treatment regimen. Chest pain is the second most common reason for an emergency department visit, with high costs associated with these visits. HeartBeam’s software solution may offer more accurate heart attack detection to triage patients and expedite treatment. The HeartBeam technology platform has not yet been evaluated by the FDA and is not approved for clinical use in the USA or other global geographies. “We believe our commercialization path is on track,” said Branislav Vajdic, PhD, CEO and founder. “The decision to include the broader patient population does not impact the scheduled submission for HeartBeam’s core technology platform for our Telehealth solution, which remains on schedule to submit in Q4 2022.” About HeartBeam, Inc. HeartBeam, Inc. is a development stage digital healthcare company with proprietary ECG telemedicine technology that will redefine the way high risk cardiovascular patients are diagnosed in an ambulatory setting at any time and any place. Its breakthrough solution employs a reusable, credit card sized, 3D vector ECG recording device and cloud-based software capable of assisting a physician in diagnosing a wide range of cardiovascular disease. HeartBeam is initially focusing on a huge unmet need of helping diagnose heart attacks in patients outside of a medical institution. No single lead ECG technology can offer this value to patients and their physicians. This underserved market is several times larger than the cardiac arrhythmia detection market based on the prevalence of patients with coronary artery disease at high risk of heart attack.

Read More

HEALTH TECHNOLOGY

Microba Life Sciences Signs Partnership With Nib-Backed Midnight Health

Microba Life Sciences Limited | May 26, 2022

Microba Life Sciences Limited has signed a strategic partnership agreement with nib Holdings Limited backed digital healthcare company Midnight Health, to deliver a personalised health service to the Australian consumer market. Under this Agreement, Midnight Health will promote, market and sell a world-first subscription-based service, known as Vidality, with its network of pharmacists to formulate personalised supplements for each customer based on their microbiome test results, leveraging the recommendations from Microba’s Analysis Platform. This personalised, pharmacy-integrated service model – delivered with trained, registered pharmacists – will bring a level of science and personalisation to an industry which commonly provides customers with one-size-fits-all solutions. Midnight Health CEO, Nic Blair said: “We are experiencing strong demand for innovative online healthcare solutions aligned to an individual needs. We already have more than 13,000 subscribers across our existing brands with strong month-on-month growth. Many of our customers are looking for gut health solutions and we are proud to bring the Vidality product to our customers in partnership with Microba”. The Agreement was signed, for an initial period of 3 years, after a successful pilot which tested the service model and product offering. It further demonstrates Microba’s scalable technology and ability to deliver evidence-based gut health solutions together with distribution partners. “Consumers are seeking personalised, evidence-based solutions to support their gut health. Together with Midnight Health, we are excited to bring the Vidality product to consumers, a truly personalised solution powered by our technology”. Microba CEO, Dr Luke Reid This delivers on an undertaking in the Company’s Prospectus to enter into an Australian partnership with a fast growth innovative consumer healthcare company. This announcement has been authorised for release by the Board. About Midnight Health Midnight Health delivers innovative online healthcare solutions through a patient-led digital platform. With the primary goal of democratising healthcare and enabling individuals to take control of their own healthcare, Midnight Health integrate telehealth technology, doctors, pharmacy network and other partners to provide a seamless patient experience for fast, convenient and discreet access to treatments, prescriptions and education through niche digital brand platforms. About Microba Life Sciences Limited Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions.

Read More

HEALTHTECH SECURITY

Health Alliance Improves Outcomes and Reduces Costs Using CareSignal’s Deviceless Remote Patient Monitoring

CareSignal, Health Alliance | June 27, 2022

Health AllianceTM, the health plan of Illinois-based Carle Health, is leading the way for rising-risk populations by launching a remote patient monitoring program powered by CareSignal. This program is part of Hally® health, the member-facing telehealth app Health Alliance uses to give its members access to tools and resources for their well-being. The partnership between Health Alliance and CareSignal aims to reduce readmissions, reduce spending, and improve members’ experience while increasing health literacy and empowering members to better self-manage their chronic conditions. The partnership is serving shared Medicare and Commercial populations and is expanding to Carle Health’s Accountable Care Organization. CareSignal’s scalable remote patient monitoring technology sends evidence-based questions directly via phone call or text message to the member. Questions focus on the member’s health status and encourage adherence to their health management plan through reporting of symptoms and daily habits while monitoring changes in risk status. Indications of worsening symptoms can trigger real-time alerts to allow for intervention, including proactive health coaching and escalation of care. Health Alliance is currently prioritizing Chronic Obstructive Respiratory Disease congestive heart failure, hypertension, asthma, and post-discharge care, and is hoping to add additional populations. Health Alliance is also bolstering its care coordination team with CareSignal’s virtual care navigators enabling them to manage a larger member population without needing additional staff. VCNs are the first to intervene with members before escalating to the Health Alliance care coordination team and/or primary care physician. By handling routine review, education and scheduling tasks when needed, the VCNs enable the Health Alliance care coordination team to work at the top of their license. The program provides increased support for members without increased touch points from providers. “Our team selected CareSignal as the best fit for our Health Alliance remote patient monitoring strategy due to its clinically validated pathways, ability to scale, and ease of use for our members. We believe by adding remote patient monitoring to our population health services, we will improve quality of care and health outcomes, expand access to care management, reduce disparities in health outcomes, enhance the member experience, and reduce hospitalizations, ED visits, and readmission rates.” Margie Zeglen, MBA, FACHE, Vice President of Population Health at Health Alliance and Carle Health “The expansion of this relationship is a result of the clinical and strategic vision that Carle and Health Alliance teammates bring to our partnership,” said Blake Marggraff, CEO of CareSignal, a Lightbeam Company. “Given the ongoing, nationwide staffing challenges that healthcare organizations face, the CareSignal team is particularly proud to be able to support Health Alliance with both the technology and clinical resources required for success. I look forward to serving even more individuals’ clinical needs while simultaneously serving a terrific client-partner.” About Health Alliance Based in Champaign, IL, Health Alliance operates in Illinois, Iowa, Indiana, Ohio, and Washington with additional licenses in Nebraska and Missouri. Health Alliance is part of Carle Health, an integrated system of healthcare services, which includes a five-hospital system as multi-specialty physician groups, as well as Carle Illinois College of Medicine and the Stephens Family Clinical Research Institute. In Illinois, Health Alliance offers employer group plans, individual plans, Medicare plans, State of Illinois Employee plans, and State of Illinois Retiree plans through Total Retiree Advantage Illinois. In Iowa, Health Alliance offers employer group plans and Medicare plans. In Washington, we offer Medicare plans and public individual plans. And in Indiana and Ohio, Health Alliance offers Medicare plans. About CareSignal – a Lightbeam Health Solutions Company CareSignal offers Deviceless Remote Patient Monitoring® which is specifically designed for value-based care by leveraging real-time, self-reported patient data and artificial intelligence to produce long-term patient engagement while identifying clinically actionable moments for proactive care delivery. Together, Lightbeam and CareSignal align best-in-class population health capabilities with proven remote engagement and monitoring solutions serving more than 42 million patient lives across the United States. Lightbeam’s vision is to shine a light on health data using analytics, and to provide the insight and capabilities healthcare clients need to ensure patients receive the right care at the right time. Learn more about solutions specific to your organization and population by visiting our website or trying a self-guided demo.

Read More

HEALTH TECHNOLOGY

WELL Forms Canadian Clinics Business Unit, Expands Credit Agreement, and Ramps up Clinic Growth

WELL Health Technologies Corp. | July 15, 2022

WELL Health Technologies Corp. a practitioner focussed digital health company positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, is pleased to announce it has formed a new legal entity called WELL Health Canada Clinics Inc. to house its Canadian omni-channel clinical businesses. These businesses include the Company's previous Primary Care, Allied Care and MyHealth Specialized Care business units. The Canadian Clinics Business Unit represents WELL's owned and operated fleet of Omni-Channel outpatient clinics leveraging WELL's highly integrated 'hybrid' brick and mortar and virtual service capabilities and includes the Company's primary care, specialized care, allied health, and diagnostics services but does not include the Company's TiaHealth.com service which is part of WELL's Virtual Services division. This business unit supports almost 1,300 healthcare practitioners who provide 1.87 million patient visits annually on a run-rate basis(2); over 40% of these patients are seen remotely via one of WELL's virtual or telehealth platforms, with the remainder treated in one of WELL's 81 Canadian clinics(3). This business is also expected to generate revenues exceeding $160 million with double digit operating Adjusted EBITDA(4) margins. Driven by WELL's consolidation and capital allocation efforts, this business has been experiencing organic growth rates approaching double digit percentage growth. The Canadian Clinics business unit is a key pillar in WELL's mission to empower practitioners. Dr. Michael Frankel, WELL's Chief Medical Officer, said "This consolidation of our Canadian clinics business provides WELL with the proper foundation to become a national health system providing the very best in highly integrated 'bricks and clicks' care. We are excited to provide healthcare practitioners with a compelling home where they are supported with exceptional front and back-office support and technology solutions so they can provide critical care to their patients. We intend on further developing our services from coast to coast." WELL will look to continue its consolidation and modernization of healthcare resources in Canada powered by its organic growth and with the help of its funding partners RBC, the Bank of Montreal, HSBC Bank Canada, The Toronto-Dominion Bank, ICICI Bank Canada and Laurentian Bank of Canada (collectively the "Lenders"). RBC is the Lead Arranger, Sole Bookrunner, and Administrative Agent on the financing. The Lenders have amended previous MyHealth credit facilities to include the newly formed Canadian Clinics Business Unit, as well as provided an extension of their credit commitments for an incremental year, extending the maturity to June 2026. The facilities are currently priced at an interest rate which is equivalent to SOFR/CDOR plus 1.25% to 3.25%(5), depending on the debt to Adjusted EBITDA ratio of the consolidated results for the Canadian Clinics Business Unit. WELL's goal is to continue to grow Canada's largest network of outpatient clinics using a combination of greenfield sites and new acquisitions. WELL is pleased to confirm that it has added a primary care clinic in Vancouver to its network and a new greenfield haemorrhoid treatment center in Hamilton, Ontario. The Company's combined investment to add these two clinics to the network is less than $100k. The combined annual revenues of the two clinics are expected to exceed $2 million in their first year under WELL and be profitable. The Company's recently announced acquisition of Calgary based InLiv, a premium provider of healthcare services in the Province of Alberta, will also be part of the Canadian Clinics Business Unit upon closing and is expected to exceed $7 million per year in revenues with 85% of such revenue reflecting recurring membership revenue. "We are thrilled to have the continued support of our banking partners and to announce the amendments to our existing Canadian credit facilities. Our ability to expand our Canadian credit agreement with favourable terms in the present challenging macroeconomic environment is not only a testament to the fantastic support we are receiving from our banking partners but also the strength of WELL's outpatient clinic business. The updated credit facilities allow us to more efficiently deploy capital towards our strategic priorities and generate more shareholder value by improving our revenue and Adjusted EBITDA per share metrics." Hamed Shahbazi, CEO and Founder of WELL WELL's objective is to continue to grow its Canadian Clinics Business Unit both organically and inorganically and continue to demonstrate market leadership as the country's first pan-Canadian clinical network with a highly integrated network of tech-enabled outpatient healthcare clinics across the country. About WELL Health Technologies Corp. WELL is a practitioner focused digital healthcare company whose overarching objective is to positively impact health outcomes to empower and support healthcare practitioners and their patients. WELL has built an innovative practitioner enablement platform that includes comprehensive end to end practice management tools inclusive of virtual care and digital patient engagement capabilities as well as Electronic Medical Records (EMR), Revenue Cycle Management (RCM) and data protection services. WELL uses this platform to power healthcare practitioners both inside and outside of WELL's own omni-channel patient services offerings. As such, WELL owns and operates Canada's largest network of outpatient medical clinics serving primary and specialized healthcare services and is the provider of a leading multi-national, multi-disciplinary telehealth offering. WELL is publicly traded on the Toronto Stock Exchange under the symbol "WELL" and on OTCQX under the symbol "WHTCF".

Read More

Spotlight

What do I do if my child suffers a concussion?  1. Remove your child from the game 2. Have your child evaluated by a qualified healthcare professional. 3. Do not return your child to play until he or she is symptom-free 4. Inform your child’s teacher and coach about the concussion.

Resources